Merck (NYSE: MRK) announced that the European Commission has approved KEYTRUDA (pembrolizumab) in combination with paclitaxel, with or without bevacizumab ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE